Graduate School of Education, Shandong Sport University, Jinan, 250102, China.
Department of Clinical Laboratory, Zibo Central Hospital, Zibo, 255000, China.
Anticancer Agents Med Chem. 2024;24(20):1457-1466. doi: 10.2174/0118715206321574240821112747.
Interleukin-15 (IL-15) was identified in 1994 as a T-cell growth factor with the capability to mimic the functions of IL-2. IL-15 engages with the IL-15Rα subunit expressed on the surface of antigen-presenting cells (APCs) and, through a trans-presentation mechanism, activates the IL-2/IL-15Rβγ complex receptor on the surface of natural killer (NK) cells and CD8+ T cells. This interaction initiates a cascade of downstream signaling pathways, playing a pivotal role in the activation, proliferation, and anti-apoptotic processes in NK cells, CD8+ T cells, and B cells. It provides a substantial theoretical foundation and potential therapeutic targets for tumor immunotherapy. Whether through active or passive immunotherapeutic strategies, IL-15 has emerged as a critical molecule for stimulating anti-tumor cell proliferation.
白细胞介素-15（IL-15）于 1994 年被鉴定为一种 T 细胞生长因子，具有模拟 IL-2 功能的能力。IL-15 与抗原呈递细胞（APCs）表面表达的 IL-15Rα 亚基结合，并通过转呈递机制激活自然杀伤（NK）细胞和 CD8+T 细胞表面的 IL-2/IL-15Rβγ 复合物受体。这种相互作用启动了一系列下游信号通路，在 NK 细胞、CD8+T 细胞和 B 细胞的激活、增殖和抗凋亡过程中发挥关键作用。它为肿瘤免疫治疗提供了重要的理论基础和潜在的治疗靶点。无论是通过主动还是被动免疫治疗策略，IL-15 已成为刺激抗肿瘤细胞增殖的关键分子。
